Education
About Us
Working with TipRanks
Follow Us
BB Biotech AG (CH:BION)
:BION
Total Valuation
BB Biotech has a market cap or net worth of CHF1.68B. The enterprise value is CHF3.79B.
Market CapCHF1.68B
Enterprise ValueCHF3.79B
Share Statistics
BB Biotech has 55,400,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding55,400,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BB Biotech’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 3.51%.
Return on Equity (ROE)0.03
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)3.51%
Return on Capital Employed (ROCE)0.04
Revenue Per Employee11.16M
Profits Per Employee7.59M
Employee Count10
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BB Biotech is 25.65. BB Biotech’s PEG ratio is -0.02.
PE Ratio25.65
PS Ratio0.00
PB Ratio1.08
Price to Fair Value0.85
Price to FCF17.07
Price to Operating Cash Flow17.07
PEG Ratio-0.02
Income Statement
In the last 12 months, BB Biotech had revenue of 111.63M and earned 75.90M in profits. Earnings per share was 1.38.
Revenue111.63M
Gross Profit111.63M
Operating Income84.40M
Pretax Income75.95M
Net Income75.90M
EBITDA80.24M
Earnings Per Share (EPS)1.38
Cash Flow
In the last 12 months, operating cash flow was 304.56M and capital expenditures 0.00, giving a free cash flow of 304.56M billion.
Operating Cash Flow304.56M
Free Cash Flow304.56M
Free Cash Flow per Share5.50
Dividends & Yields
BB Biotech pays an annual dividend of CHF1.8, resulting in a dividend yield of 5.89%
Dividend Per ShareCHF1.8
Dividend Yield5.89%
Payout Ratio-46.10%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.09
52-Week Price Change-18.42%
50-Day Moving Average29.35
200-Day Moving Average33.24
Relative Strength Index (RSI)57.53
Average Volume (3m)75.18K
Important Dates
BB Biotech upcoming earnings date is Jul 25, 2025, Before Open (Confirmed).
Last Earnings DateApr 25, 2025
Next Earnings DateJul 25, 2025
Ex-Dividend DateMar 21, 2025
Financial Position
BB Biotech as a current ratio of 19.88, with Debt / Equity ratio of 4.42%
Current Ratio19.88
Quick Ratio19.88
Debt to Market Cap0.06
Net Debt to EBITDA1.46
Interest Coverage Ratio0.00
Taxes
In the past 12 months, BB Biotech has paid 54.00K in taxes.
Income Tax54.00K
Effective Tax Rate<0.01
Enterprise Valuation
BB Biotech EV to EBITDA ratio is 25.72, with an EV/FCF ratio of 6.78.
EV to Sales18.49
EV to EBITDA25.72
EV to Free Cash Flow6.78
EV to Operating Cash Flow6.78
Balance Sheet
BB Biotech has CHF2.41B in cash and marketable securities with CHF117.50M in debt, giving a net cash position of -CHF2.29B billion.
Cash & Marketable SecuritiesCHF2.41B
Total DebtCHF117.50M
Net Cash-CHF2.29B
Net Cash Per Share-CHF41.33
Tangible Book Value Per ShareCHF41.57
Margins
Gross margin is 100.00%, with operating margin of 75.61%, and net profit margin of 67.99%.
Gross Margin100.00%
Operating Margin75.61%
Pretax Margin68.04%
Net Profit Margin67.99%
EBITDA Margin71.88%
EBIT Margin71.96%
Analyst Forecast
The average price target for BB Biotech is CHF66.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF66.00
Price Target Upside116.04% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast1786.54%
EPS Growth Forecast-238.40%